Evidence map›Paper›PMID 41077782›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Modulation of the unfolded protein response with a C-terminal fragment of MANF facilitates recovery in models of multiple sclerosis.

Tapani K Koppinen, Carolina R Reyes, Jinhan Nam, Aastha Singh, Shibajee Mandal, Liam Beckett, Alba Montedeoca, Tuomas A E Kallionpää, Maria Lindahl, Francisco J Rivera and 1 more

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tapani K KoppinenDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Electronic address: tapani.z.koppinen@helsinki.fi.
Carolina R ReyesTranslational Regenerative Neurobiology Group (TReN), Molecular and Integrative Biosciences Research Programme (MIBS), Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
Jinhan NamDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Aastha SinghDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Shibajee MandalDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Liam BeckettDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Alba MontedeocaDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Tuomas A E KallionpääDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Maria LindahlInstitute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.
Francisco J RiveraTranslational Regenerative Neurobiology Group (TReN), Molecular and Integrative Biosciences Research Programme (MIBS), Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
Merja H VoutilainenDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation in multiple sclerosis leads to chronic activation of a cellular stress mechanism, the unfolded protein response (UPR), which is thought to both exacerbate neuroinflammation and prevent regenerative tissue responses such as remyelination. The UPR-modulating protein MANF has shown great promise for attenuating chronic UPR activation and enhancing tissue regeneration in various disease models but does not reach the CNS when given peripherally. We utilized C-MANF, a C-terminal fragment of MANF, and showed that subcutaneous administration of C-MANF promoted motor function recovery and tissue regeneration in a mouse model of autoimmune demyelination. We demonstrated that C-MANF suppresses neuroinflammatory activation and facilitates the recovery of oligodendrocytes after demyelination, while reducing long-term activation of the UPR. Furthermore, we showed that C-MANF enhances myelination of primary OPCs in culture, that promotion of remyelination in cerebellar organotypic slice cultures is dependent on UPR-modulation, and that exogenously applied C-MANF suppresses chronic activation of all three UPR pathways in oligodendroglia. Finally, we showed that demyelination in MANF-deficient brains leads to extensive neuroinflammation and CNS degeneration, implicating UPR modulation by MANF as a key component in tissue responses to demyelination. Altogether, we show that UPR modulation with C-MANF is a promising new therapeutic approach for treating neuroinflammatory demyelination.

Indexed as

Multiple SclerosisUnfolded Protein ResponseAnimalsDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalHumansMiceNerve Growth FactorsOligodendrogliaRemyelinationMANF protein, mouseNerve Growth FactorsER homeostasismultiple sclerosisneuroinflammationproteostasisremyelinationunfolded protein response

Identifiers

PMID41077782
PMCPMC12882342

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.